×

What's Next For Repligen Stock After A 12% Fall In A Month?

Published Oct 12 2021 at 1:15 PM GMT
Key
Points
  • The stock price of Repligen (NASDAQ: RGEN), aU S-aed life sciences company involved in production of materials used in the manufacture of biological drugs, has seen a 12% drop over the last twenty-one trading days.
  • The company last month announced the acquisition of Avitide - a privately held.




Trending

Stats

  • Published Oct 12, 2021 1:15 PM GMT